The Bill 118 hr 8574, also known as the 340B ACCESS Act, aims to address issues related to the 340B Drug Pricing Program. This program requires drug manufacturers to provide discounts on outpatient drugs to certain healthcare facilities that serve low-income and vulnerable populations.
The 340B ACCESS Act seeks to improve transparency and accountability within the program by requiring participating healthcare facilities to report on how they are using the discounts they receive. This information will be made publicly available in order to ensure that the discounts are being used to benefit the intended populations.
Additionally, the bill includes provisions to address concerns about the increasing costs of prescription drugs. It requires drug manufacturers to provide additional discounts on drugs that have seen significant price increases, in order to help mitigate the financial burden on patients and healthcare facilities.
Overall, the 340B ACCESS Act aims to strengthen the 340B Drug Pricing Program and ensure that it is effectively serving its intended purpose of providing affordable medications to low-income and vulnerable populations.